SC451 — IND submission
2026
Goal is to file IND and begin Phase 1/2 trial this yearSource filing
SANA biotech catalysts & pipeline
SANA BIOTECHNOLOGY INC · Data as of 2026-10-25
Upcoming catalysts
SG293 — Initial data
2026
We plan to develop SG293 in a range of B cell cancers and B cell mediated autoimmune diseases and expect to generate initial clinical data as early as this year.Source filing
SG293 — IND submission
2026
Expect to file IND for SG299 in a B-cell related disease as early as 2026Source filing
SG293 — Initial data
1H 2027
SG293 in non-Hodgkin lymphoma – potential to share first-in-human data in 1H 2027Source filing
SG293 — IND submission
2027
We intend to explore SG293 in both B-cell cancers and B-cell mediated autoimmune diseases and expect to file an IND for SG293 as early as 2027.Source filing